Popular diabetes drug semaglutide under scrutiny for bone effects

NCT ID NCT07165158

Not yet recruiting Disease control Sponsor: The First Affiliated Hospital of Xiamen University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at whether semaglutide (a diabetes drug that lowers blood sugar and helps with weight loss) affects bone density and fracture risk in people with type 2 diabetes. About 150 adults aged 50–75 will get either semaglutide plus metformin or metformin alone for 12 months. Researchers will then compare bone density, fracture rates, and bone health markers between the two groups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide combined with metformin
What this could lead to: If it works, this could show that semaglutide is safe for bones and may even help prevent fractures in people with type 2 diabetes.
What could go wrong: This is a small, early-phase trial (150 people) that hasn't started yet. The results may not apply to everyone, and weight loss from semaglutide could actually weaken bones.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoporosis Osteoporotic Fractures type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSTEOPOROSIS OSTEOPOROSIS FRACTURE T2DM

Contacts and locations

Locations

The First Affiliated Hospital of Xiamen University

Xiamen, Fujian, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.